Data are limited, however. In mice, ingesting exercise mimetics appeared to improve depressive-like behaviors, and the ...

Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets –– Topline data for ...

A recent UC Santa Cruz study, published in Nature Communications scientific journal, uncovered clues in a decadeslong mystery ...

In former college and professional football players, a new study has found higher levels of inflammation were associated with ...

Q4 2025 Earnings Call Transcript February 24, 2026Kiniksa Pharmaceuticals, Ltd. misses on earnings expectations.

Although urinary tract infections (UTIs) are typically minor—albeit painful—health issues for most people, they can pose ...

On the same day, February 18, Reuters reported that Eli Lilly signed an exclusive licensing agreement with CSL Limited for clazakizumab, an anti-interleukin-6 (IL-6) monoclonal antibody. CSL is an ...

CSL Ltd. is out-licensing its interleukin-6 (IL-6) monoclonal antibody, clazakizumab, to Eli Lilly and Co. in a deal that brings CSL $100 million in up-front fees. A CSL spokesperson told BioWorld the ...

The Australian company will retain rights for an end-stage kidney disease indication currently being tested in a Phase 3 trial while Lilly explores other uses.

Eli Lilly is paying $100 million upfront (PDF) for the right to develop CSL’s phase 3-stage IL-6 antibody that had previously been explored for organ transplant rejection.

Australia's CSL said on Wednesday it has granted Eli Lilly certain rights to develop and commercialize clazakizumab, an ...

The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...